Clinical Trials Logo

Clinical Trial Summary

Mechanical ventilation commonly is associated with patient agitation requiring sedation to alleviate discomfort and reduce excessive central respiratory drive. Upon recovery from acute respiratory failure, sedation is reduced to facilitate the withdrawal of ventilatory support. In some patients, abrupt reduction in sedation provokes severe agitation that causes catecholamine release resulting in severe hypertension, tachycardia and tachypnea. This requires increased sedation to bring hemodynamic and respiratory function under control.

Dexmedetomidine is an alpha-2 receptor agonist with both sedative and analgesic properties that allows for the reduction in the anesthetic and analgesic requirements in the perioperative setting. In addition to its sedative effects, alpha-2 receptor stimulation in the central nervous system inhibits sympathetic activity and reduces plasma epinephrine and norepinephrine levels, thereby lowering both arterial blood pressure and heart rate. Because alpha-2 receptor stimulation does not cause respiratory depression, dexmedetomidine may facilitate the transition to unassisted breathing in profoundly agitated patients. The investigators will prospectively evaluate dexmedetomidine in 30 patients who could not be extubated because of agitation with hemodynamic instability and tachypnea.

The purpose of this study is to test if a larger prospective randomized controlled pilot study can show that dexmedetomidine facilitates weaning and extubation in patients who have failed previous attempts because of agitation and hyperdynamic cardiopulmonary response.


Clinical Trial Description

Sixty patients who are admitted to the surgical intensive care unit (ICU) at San Francisco General Hospital will be referred to the investigators for enrollment into a prospective, unblinded, randomized study of dexmedetomidine. Each patient will be considered by the critical care team as a suitable candidate for weaning and extubation based on inclusion/ exclusion criteria. Pregnant patients will not be enrolled and this will be determined by a negative urine or serum pregnancy test from admission. If none is available a pregnancy test will be performed prior to enrollment. Patients considered difficult to wean will be based on the following criteria:

Eligible patients will be randomized to either the control arm or the dexmedetomidine arm in a 1:1 ratio by using sealed envelopes.

Patient randomized to the control arm will be extubated per standard hospital protocol. This arm of the study will be observational and these patients will be extubated by the attending physician for that patient whenever they are hemodynamically stable enough to tolerate another weaning trial. The study team will collect the same data points for the control arm as in the dexmedetomidine arm. This includes ABGs, heart rate, mean blood pressure, respiratory rate and RASS scores (see description below of data points and collection time points.) Arterial blood gases will be drawn for the control arm of the study.

Patients on the dexmedetomidine arm will be started on dexmedetomidine at either 0.5 mcg/kg/hr or 0.7 mcg/kg/hr 1 hour prior to extubation. The drug calculation was based upon an average taken between the patient's measured and predicted body weight. Background sedation will be generally facilitated with lorazepam, midazolam or propofol, while analgesia will be maintained with either fentanyl or hydromorphine. After starting dexmedetomidine background sedation and analgesia will be titrated down and discontinued if possible. Analgesia levels also will be reduced if tolerated. Dexmedetomidine will be titrated according to blood pressure, RASS and heart rate response and the dose will be lowered only after sedation is discontinued or markedly reduced. Aerosolized lidocaine (20 mg) therapy will be initiated prior to the weaning trial to prevent excessive coughing in all patients.

Shortly after the dexmedetomidine infusion is started, PSV will be commenced at 5 cm H2O above 5 cm H2O of continuous positive airway pressure (CPAP). Patients will be weaned to CPAP and evaluated for extubation.

1.) Arterial blood gases will be obtained in all patients with an arterial line at three points in time: just prior to dexmedetomidine infusion, during the CPAP trial, and approximately 30 minutes after extubation.

3.) Heart rate, mean blood pressure, RASS, and respiratory rate will be collected at fifteen minute intervals 1 hour prior to dexmedetomidine infusion, during the 1 hour infusion of dexmedetomidine prior to the extubation then 5, 15, 30, 45, 60, 90 and 120 minutes after extubation for a total of 4 hours of data collection. ;


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00464490
Study type Interventional
Source University of California, San Francisco
Contact
Status Terminated
Phase N/A
Start date November 2007
Completion date December 2012

See also
  Status Clinical Trial Phase
Recruiting NCT02922595 - Comparison of iLTS-D® and ILMA® for Intubation With Fiberoptic Control N/A
Completed NCT02051400 - Evaluation of McGrath® MAC Video Laryngoscope N/A
Completed NCT01965938 - RIFL (Rigid and Flexing Laryngoscope) vs. Fiberoptic Bronchoscope N/A
Completed NCT02769819 - Identification of Morphological Characteristics to Predict Difficult Endotracheal Intubation Using a Flexible Fiberscope N/A
Completed NCT02362568 - Study of Interest on Cervical Ultrasound Exploration for Association With Difficult Intubation N/A
Completed NCT01692522 - Comparison of the Laryngeal Mask Ambu Aura-i Versus AirQ in Children N/A
Recruiting NCT03035786 - Airway Code Calls - Survey of Management N/A
Completed NCT02290249 - Intubation of a Pediatric Manikin in Difficult Airway by Novice Personnel: A Comparison of Glidescope and Airtraq Phase 4
Completed NCT02326896 - MACOCHA Score Predicts Intubation Failure N/A
Completed NCT01984970 - McGrath Series 5 Videolaryngoscope for Double-lumen Tube Intubation N/A
Completed NCT01474213 - Sedation Effect of Dexmedetomidine Versus Remifentanil to Fibreoptic Intubation Phase 4
Not yet recruiting NCT02430415 - Laryngoscope-assisted Lightwand Intubation and Cervical Spine Motion N/A
Completed NCT01375634 - Nasogastric Tube Insertion Using Midazolam in the Emergency Department Phase 4
Completed NCT01464489 - Intubation Time With Low Dose Rocuronium N/A
Terminated NCT01075789 - Using Lignocaine Spray and Gel to Reduce the Pain Associated With Nasogastric Tube Insertion in Children N/A
Recruiting NCT02501577 - Comparison of Various Supraglottic Airway Devices for Fiberoptical Guided Tracheal Intubation N/A
Completed NCT02566135 - I-gel Versus Classic-Laryngeal Mask Airway (C-LMA) as a Conduit for Tracheal Intubation Using Ventilating Bougie N/A
Recruiting NCT02493478 - Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs
Completed NCT02198742 - A Comparison Between Two Video Laryngoscopes,in Successfully Intubating Pediatric Mannequins w/wo Difficult Airways Phase 1
Completed NCT02788253 - Mallampati Classification vs Best Visible Mallampati for Prediction of Difficult Tracheal Intubation